Aging population of tracheal, bronchus, and lung cancer: global, regional, and national burden—insights from the Global Burden of Disease Study 2021
Open Access
- 1 August 2025
- journal article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (8) , 5547-5560
Abstract
Background: Tracheal, bronchus, and lung (TBL) cancer is the leading cause of cancer-related deaths globally and accounts for the highest incidence among all cancers. We used the Global Burden of Disease (GBD) data from 1990 to 2021 to analyze the burden of TBL cancer by age, sex, and socio-demographic index (SDI) to provide new insights. Methods: We utilized GBD 2021 methodologies to calculate the percentage change (PC) in TBL cancer age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and disability-adjusted life-years (DALYs). Age-period-cohort models predicted TBL cancer incidence and mortality trends for 2035. The elderly population (EP) was stratified as vs. ≥70 years. Results: In 2021, TBL cancer accounted for 2.28 million [95% uncertainty interval (UI): 2.06–2.51] new cases, 2.04 million (95% UI: 1.88–2.19) deaths, and 45.9 million (95% UI: 42.3–49.3) DALYs. ASIR in males declined significantly (PC =−11.2%, 95% UI: −21.7% to −0.4%), while it slightly increased in females (PC =0.9%, 95% UI: −8.3% to 11.4%). Non-elderly (vs. 15.74 per 100,000). Mortality among elderly males declined in some regions, while mortality among females, especially in low-SDI countries, showed no improvement and sometimes increased. Projections to 2035 suggest that ASIR and ASMR will continue rising in older women while declining in males. Conclusions: The burden of TBL cancer is projected to rise with population aging, particularly among women. The increasing ASIR and ASMR in females warrant urgent investigation of risk factors and targeted preventive measures to curb this trend.Keywords
This publication has 28 references indexed in Scilit:
- Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA: A Cancer Journal for Clinicians, 2024
- Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Cancer statistics, 2024CA: A Cancer Journal for Clinicians, 2024
- Trends in Lung Cancer Incidence and Mortality (1990-2019) in the United States: A Comprehensive Analysis of Gender and State-Level DisparitiesJCO Global Oncology, 2023
- Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019Cancer Medicine, 2022
- Sex and Gender Differences in Lung Cancer and Chronic Obstructive Lung DiseaseEndocrinology, 2021